Clinical Trial Update: Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Firmonertinib combined with definitive radiotherapy for stage III unresectable EGFR uncommon mutant non-small cell lung cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Firmonertinib (firmonertinib)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: NSCLC (Non-small Cell Lung Carcinoma), Stage III | Phase 2 | Status: NOT_YET_RECRUITING